A Phase 2 interventional study of dabigatran with ASA and dabigatran with ASA in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 38 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.
Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 4 in phase 2, and was the 3rd registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 22
First in 2003; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 502 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 174 across the 35 interventional studies. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 35 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
45 studies in Atrial Fibrillation by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 45 finished, 44 (98%) have results posted.
Among the 45 studies in Atrial Fibrillation by Boehringer Ingelheim, this one is one of 2 that started in 2003, is one of 3 in phase 2, and was the 5th registered.
Boehringer Ingelheim’s Atrial Fibrillation studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 35 studies testing dabigatran in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 45 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the safety of different doses of BIBR 1048, alone or in combination with acetylsalicylic acid (ASA), as determined by the rates of bleeding and other adverse events.
A secondary objective of this trial is to evaluate the anticoagulant effect of different doses of BIBR 1048, based on the reduction of plasma concentrations of D-dimer, a laboratory marker for activated coagulation in patients with atrial fibrillation (AF), and to correlate bleeding and other events with pharmacokinetic (PK) and pharmacodynamic (PD) data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An additional risk factor for stroke, i.e. one or more of the following conditions/events:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
Drug: dabigatran without ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
Drug: dabigatran with ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
Drug: dabigatran with ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening
Drug: dabigatran without ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
Drug: dabigatran with ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
Drug: dabigatran with ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening
Drug: dabigatran without ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
Drug: dabigatran with ASA
Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
Drug: dabigatran with ASA
once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
Drug: warfarin
Drug pages: Dabigatran · Aspirin
dose comparison in combination
Drug pages: Dabigatran · Aspirin
dose comparison in combination
Drug pages: Dabigatran · Aspirin
dose comparison in combination
Drug pages: Dabigatran · Aspirin
dose comparison in combination
Drug pages: Dabigatran · Aspirin
dose comparison in combination
Drug pages: Dabigatran · Aspirin
dose comparison in combination
comparator
dose comparison
dose comparison
dose comparison
Number of Participants With Fatal or Life-threatening Major Bleeding Events
Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more
Time frame: 12 weeks
Number of Participants With Minor/Relevant Bleeding Events
Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm\^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding
Time frame: 12 weeks
Number of Participants With Minor/Nuisance Bleeding Events
All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.
Time frame: 12 weeks
Number of Participants With Thromboembolic Events: Composite Endpoint
Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality
Time frame: 12 weeks
Number of Participants With Thromboembolic Events: Ischemic Stroke
Occurence of an ischemic stroke (fatal or non-fatal)
Time frame: 12 weeks
Thromboembolic Events: Number of Participants With Transient Ischemic Attack
Occurence of a transient ischemic attack
Time frame: 12 weeks
Thromboembolic Events: Number of Participants With Systemic Thromboembolism
Occurence of a systemic thromboembolism
Time frame: 12 weeks
Thromboembolic Events: Number of Participants With Myocardial Infarction
Occurence of a myocardial infarction
Time frame: 12 weeks
Thromboembolic Events: Number of Participants With Other Major Cardiac Events
Occurence of other major adverse cardiac events
Time frame: 12 weeks
Thromboembolic Events: Number of Participants Who Died
Occurence of death by all causes
Time frame: 12 weeks
D-dimer: Difference From Baseline
Difference in D-dimer from baseline to last available value
Time frame: baseline and 12 weeks
Soluble Fibrin: Difference From Baseline
Difference from baseline to visit 7
Time frame: baseline and 12 weeks
11-dehydrothromboxane B2 (TXB2): Difference From Baseline
Difference from baseline to visit 7
Time frame: baseline and 12 weeks
Ecarin Clotting Time (ECT): Difference From Baseline
Time frame: baseline and 12 weeks
Activated Partial Thromboplastin Time (aPTT): Difference From Baseline
Time frame: baseline and 12 weeks
Trough Plasma Concentration of Dabigatran (BIBR 953)
The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.
Time frame: 12 weeks
Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline
Increase of AST to more than two times the baseline value
Time frame: 12 weeks
Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline
Increase of AP to more than two times the baseline value
Time frame: 12 weeks
Number of Participants With Increase of Bilirubin to >2*Baseline
Increase of Bilirubin to more than two times the baseline value
Time frame: 12 weeks
Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline
Number of Participants with Increase of ALT to more than two times the baseline value
Time frame: 12 weeks
Severity of Adverse Events
Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.
Time frame: 12 weeks
| Milestone | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 58 | 20 | 27 | 99 | 34 | 33 | 98 | 33 | 30 | 70 |
| Completed | 56 | 18 | 26 | 91 | 32 | 32 | 90 | 27 | 24 | 68 |
| Not completed | 2 | 2 | 1 | 8 | 2 | 1 | 8 | 6 | 6 | 2 |
| Withdrew: Adverse event | 2 | 2 | 1 | 6 | 1 | 1 | 6 | 6 | 4 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 |
Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Fatal or Life-threatening Major Bleeding Events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm\^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Minor/Relevant Bleeding Events | 0 | 1 | 1 | 9 | 2 | 2 | 6 | 4 | 3 | 4 |
All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Minor/Nuisance Bleeding Events | 2 | 1 | 2 | 6 | 6 | 5 | 9 | 7 | 9 | 9 |
Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Thromboembolic Events: Composite Endpoint | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of an ischemic stroke (fatal or non-fatal)
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| None | 58 | 19 | 27 | 99 | 34 | 33 | 98 | 33 | 30 | 70 |
| Fatal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Fatal | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Both | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of a transient ischemic attack
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Thromboembolic Events: Number of Participants With Transient Ischemic Attack | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of a systemic thromboembolism
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Thromboembolic Events: Number of Participants With Systemic Thromboembolism | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of a myocardial infarction
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| None | 58 | 20 | 27 | 99 | 34 | 33 | 98 | 33 | 30 | 70 |
| Fatal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Fatal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Both | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of other major adverse cardiac events
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Thromboembolic Events: Number of Participants With Other Major Cardiac Events | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurence of death by all causes
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Thromboembolic Events: Number of Participants Who Died | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Difference in D-dimer from baseline to last available value
| ng/ml | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| D-dimer: Difference From Baseline | 22.3 ± 65.4 | 12.3 ± 25.3 | 50.2 ± 182.8 | 8.1 ± 41.6 | 29.1 ± 90.4 | 8.6 ± 49.2 | 4.2 ± 95.8 | 11.3 ± 82.2 | -7.9 ± 40.9 | -5.8 ± 50.6 |
Difference from baseline to visit 7
| µg/ml | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Soluble Fibrin: Difference From Baseline | 3.2 ± 22.0 | 0.9 ± 2.3 | 1.2 ± 8.4 | 0.3 ± 5.1 | -2.0 ± 9.9 | -1.3 ± 8.8 | 2.3 ± 26.8 | -0.7 ± 4.6 | -1.9 ± 12.0 | 0.1 ± 4.0 |
Difference from baseline to visit 7
| pg/mg Creatinine | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| 11-dehydrothromboxane B2 (TXB2): Difference From Baseline | 596.5 ± 2896.3 | -1816.8 ± 2186.1 | -2779.8 ± 2953.3 | 922.0 ± 3874.0 | -1988.6 ± 2187.5 | -1125.9 ± 3566.6 | 1059.7 ± 2216.8 | -1822.6 ± 2381.7 | -1337.8 ± 2279.2 | 203.5 ± 2109.0 |
| seconds | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ecarin Clotting Time (ECT): Difference From Baseline | 9.7 ± 8.2 | 12.0 ± 10.7 | 12.0 ± 9.6 | 31.9 ± 26.2 | 42.5 ± 29.2 | 32.7 ± 23.1 | 63.6 ± 44.8 | 70.8 ± 60.3 | 74.0 ± 70.5 | 3.1 ± 2.5 |
| seconds | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Activated Partial Thromboplastin Time (aPTT): Difference From Baseline | 6.4 ± 5.6 | 8.3 ± 6.1 | 8.8 ± 9.4 | 13.5 ± 18.3 | 24.9 ± 26.1 | 14.5 ± 11.5 | 25.0 ± 12.4 | 23.4 ± 12.7 | 27.2 ± 24.2 | 8.8 ± 6.7 |
The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.
| ng/ml | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trough Plasma Concentration of Dabigatran (BIBR 953) | 29.1 ± 16.6 | 30.4 ± 16.6 | 31.8 ± 20.0 | 82.8 ± 54.3 | 103.2 ± 69.0 | 90.1 ± 52.5 | 188.0 ± 117.3 | 203.7 ± 123.9 | 207.6 ± 108.7 | NA ± NA |
Increase of AST to more than two times the baseline value
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| No | 57 | 20 | 24 | 93 | 32 | 31 | 95 | 31 | 30 | 68 |
| Yes | 1 | 0 | 3 | 6 | 2 | 2 | 2 | 1 | 0 | 1 |
Increase of AP to more than two times the baseline value
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| No | 58 | 20 | 27 | 98 | 33 | 33 | 97 | 32 | 29 | 69 |
| Yes | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
Increase of Bilirubin to more than two times the baseline value
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| No | 55 | 18 | 25 | 86 | 31 | 33 | 88 | 29 | 29 | 63 |
| Yes | 3 | 2 | 2 | 13 | 3 | 0 | 9 | 3 | 1 | 6 |
Number of Participants with Increase of ALT to more than two times the baseline value
| Participants | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| No | 55 | 18 | 26 | 95 | 33 | 32 | 93 | 31 | 30 | 64 |
| Yes | 3 | 2 | 1 | 4 | 1 | 1 | 4 | 1 | 0 | 5 |
Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.
| participants | D50bid | D50qd | D50bid + ASA81qd | D50bid + ASA325qd | D150bid | D150qd | D150bid + ASA81qd | D150qd + ASA81qd | D150bid + ASA325qd | D150qd + ASA325qd | D300bid | D300qd | D300bid + ASA81qd | D300qd + ASA81qd | D300bid + ASA325qd | D300qd + ASA325qd | Warfarin, Dosed to Target INR 2.0 to 3.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | 24 | 0 | 9 | 16 | 54 | 1 | 23 | 0 | 17 | 0 | 47 | 1 | 23 | 2 | 23 | 1 | 30 |
| Moderate | 13 | 0 | 6 | 7 | 19 | 0 | 9 | 0 | 4 | 0 | 23 | 0 | 5 | 1 | 11 | 1 | 14 |
| Severe | 3 | 0 | 1 | 1 | 4 | 0 | 2 | 0 | 1 | 0 | 6 | 0 | 1 | 0 | 2 | 0 | 2 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D50bid | — | 5/59 (8.5%) | 20/59 (33.9%) |
| D50qd | — | 0/1 (0%) | 0/1 (0%) |
| D50bid + ASA81qd | — | 2/21 (9.5%) | 9/21 (42.9%) |
| D50bid + ASA325qd | — | 1/27 (3.7%) | 14/27 (51.9%) |
| D150bid | — | 10/100 (10%) | 43/100 (43%) |
| D150qd | — | 0/3 (0%) | 1/3 (33.3%) |
| D150bid + ASA81qd | — | 4/36 (11.1%) | 19/36 (52.8%) |
| D150qd + ASA81qd | — | 0/1 (0%) | 0/1 (0%) |
| D150bid + ASA325qd | — | 2/33 (6.1%) | 15/33 (45.5%) |
| D150qd + ASA325qd | — | 0/1 (0%) | 0/1 (0%) |
| D300bid | — | 3/105 (2.9%) | 35/105 (33.3%) |
| D300qd | — | 0/3 (0%) | 1/3 (33.3%) |
| D300bid + ASA81qd | — | 4/34 (11.8%) | 20/34 (58.8%) |
| D300qd + ASA81qd | — | 0/2 (0%) | 2/2 (100%) |
| D300bid + ASA325qd | — | 4/30 (13.3%) | 18/30 (60%) |
| D300qd + ASA325qd | — | 0/1 (0%) | 1/1 (100%) |
| Warfarin | — | 2/70 (2.9%) | 22/70 (31.4%) |
| Event | D50bid | D50qd | D50bid + ASA81qd | D50bid + ASA325qd | D150bid | D150qd | D150bid + ASA81qd | D150qd + ASA81qd | D150bid + ASA325qd | D150qd + ASA325qd | D300bid | D300qd | D300bid + ASA81qd | D300qd + ASA81qd | D300bid + ASA325qd | D300qd + ASA325qd | Warfarin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/59 | 0/1 | 0/21 | 0/27 | 1/100 | 0/3 | 2/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| Acute coronary syndromeCardiac disorders | 0/59 | 0/1 | 1/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 1/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| Atrial thrombosisCardiac disorders | 0/59 | 0/1 | 1/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| Cerebrovascular accidentNervous system disorders | 0/59 | 0/1 | 1/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| Renal infarctRenal and urinary disorders | 0/59 | 0/1 | 1/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| IleusGastrointestinal disorders | 0/59 | 0/1 | 0/21 | 1/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 0/1 | 0/70 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 1/34 | 0/2 | 1/30 | 0/1 | 0/70 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 1/30 | 0/1 | 0/70 |
| Rectal haemorrhageGastrointestinal disorders | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 1/30 | 0/1 | 0/70 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 1/30 | 0/1 | 0/70 |
| Event | D50bid | D50qd | D50bid + ASA81qd | D50bid + ASA325qd | D150bid | D150qd | D150bid + ASA81qd | D150qd + ASA81qd | D150bid + ASA325qd | D150qd + ASA325qd | D300bid | D300qd | D300bid + ASA81qd | D300qd + ASA81qd | D300bid + ASA325qd | D300qd + ASA325qd | Warfarin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 1/59 | 0/1 | 2/21 | 0/27 | 1/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 0/2 | 0/30 | 1/1 | 0/70 |
| DizzinessNervous system disorders | 3/59 | 0/1 | 1/21 | 3/27 | 4/100 | 0/3 | 2/36 | 0/1 | 1/33 | 0/1 | 4/105 | 0/3 | 2/34 | 1/2 | 5/30 | 1/1 | 2/70 |
| Abdominal painGastrointestinal disorders | 1/59 | 0/1 | 0/21 | 0/27 | 1/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 2/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 1/70 |
| NauseaGastrointestinal disorders | 2/59 | 0/1 | 2/21 | 0/27 | 4/100 | 0/3 | 1/36 | 0/1 | 1/33 | 0/1 | 1/105 | 0/3 | 2/34 | 1/2 | 1/30 | 0/1 | 0/70 |
| VomitingGastrointestinal disorders | 1/59 | 0/1 | 0/21 | 2/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 0/70 |
| FatigueGeneral disorders | 1/59 | 0/1 | 0/21 | 2/27 | 5/100 | 0/3 | 1/36 | 0/1 | 0/33 | 0/1 | 3/105 | 0/3 | 5/34 | 1/2 | 1/30 | 0/1 | 3/70 |
| Sensation of pressureGeneral disorders | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 0/70 |
| Alanine aminotransferase increasedInvestigations | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 1/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 0/70 |
| Aspartate aminotransferase increasedInvestigations | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 1/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 0/70 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/59 | 0/1 | 0/21 | 0/27 | 0/100 | 0/3 | 0/36 | 0/1 | 0/33 | 0/1 | 0/105 | 0/3 | 0/34 | 1/2 | 0/30 | 0/1 | 0/70 |
| Age, Continuous(Years) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.0 ± 8.8 | 70.1 ± 9.4 | 71.6 ± 8.1 | 69.7 ± 7.7 | 72.1 ± 9.0 | 69.7 ± 8.0 | 69.0 ± 9.1 | 71.8 ± 7.2 | 68.6 ± 7.1 | 69.0 ± 8.3 | 69.7 ± 8.3 |
| Sex: Female, Male(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 4 | 5 | 15 | 8 | 8 | 19 | 7 | 2 | 11 | 91 |
| Male | 46 | 16 | 22 | 84 | 26 | 25 | 79 | 26 | 28 | 59 | 411 |
| Baseline documentation regarding the atrial fibrillation(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Persistent | 20 | 9 | 10 | 43 | 13 | 10 | 37 | 14 | 12 | 27 | 195 |
| Permanent | 23 | 9 | 11 | 35 | 11 | 16 | 37 | 10 | 14 | 26 | 192 |
| Paroxysmal | 15 | 2 | 6 | 21 | 10 | 7 | 24 | 9 | 4 | 17 | 115 |
| Baseline documentation regarding stroke(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 54 | 18 | 24 | 93 | 30 | 30 | 91 | 31 | 26 | 62 | 459 |
| Yes | 4 | 2 | 3 | 6 | 4 | 3 | 7 | 2 | 4 | 8 | 43 |
| Baseline documentation regarding transient ischemic attack(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 49 | 20 | 25 | 88 | 31 | 31 | 90 | 30 | 26 | 63 | 453 |
| Yes | 9 | 0 | 2 | 11 | 3 | 2 | 8 | 3 | 4 | 7 | 49 |
| Baseline documentation regarding transient ischemic attack or stroke(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 45 | 18 | 23 | 82 | 27 | 28 | 85 | 28 | 22 | 57 | 415 |
| Yes | 13 | 2 | 4 | 17 | 7 | 5 | 13 | 5 | 8 | 13 | 87 |
| Baseline documentation regarding hypertension(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 17 | 10 | 8 | 21 | 13 | 14 | 24 | 8 | 10 | 21 | 146 |
| Yes | 41 | 10 | 19 | 78 | 21 | 19 | 74 | 25 | 20 | 49 | 356 |
| Baseline documentation regarding symptomatic heart failure(Participants) | BIBR 1048 50 mg b.i.d | BIBR 1048 50 mg b.i.d + ASA 81 mg q.d. | BIBR 1048 50 mg b.i.d + ASA 325 mg qd | BIBR 1048 150 mg b.i.d | BIBR 1048 150 mg b.i.d + ASA 81 mg qd | BIBR 1048 150 mg b.i.d + ASA 325 mg qd | BIBR 1048 300 mg b.i.d | BIBR 1048 300 mg b.i.d + ASA 81 mg qd | BIBR 1048 300 mg b.i.d + ASA 325 mg qd | Warfarin, Dosed to Target INR 2.0 to 3.0 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 41 | 12 | 17 | 73 | 20 | 21 | 85 | 20 | 20 | 46 | 355 |
| Yes | 17 | 8 | 10 | 26 | 14 | 12 | 13 | 13 | 10 | 24 | 147 |
8 further baseline measures are reported on the registry.
The record gives a start of Sep 2003 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Aspirin